Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • immunology

    - PMLiVE

    Boehringer Ingelheim and CDR-Life agree on deal worth up to $570m

    The deal focuses on T cell-based therapies for autoimmune disease

    - PMLiVE

    BMS granted FDA priority review for Breyanzi in marginal zone lymphoma

    The disease accounts for approximately 7% of all non-Hodgkin lymphoma cases

    - PMLiVE

    AbbVie shares promising phase 3 results for Rinvoq in severe alopecia areata

    Around 700,000 people in the US are living with some form of the autoimmune disease

    - PMLiVE

    BMS and Bain Capital launch new company to develop immunology therapies

    The newly formed company has in-licensed five investigational immunology drugs from BMS

    - PMLiVE

    AbbVie gains rights to IGI’s phase 1 trispecific engager in deal worth over $1.9bn

    ISB 2001 is in early-stage clinical development for relapsed/refractory multiple myeloma

    - PMLiVE

    AbbVie to expand immunology capabilities with $2.1bn Capstan acquisition

    The deal includes a CAR-T therapy in phase 1 development for B cell-mediated autoimmune diseases

    - PMLiVE

    BMS and BioNTech partner on solid tumour candidate in deal worth over $11bn

    BioNTech’s BNT327 is being evaluated in multiple clinical trials, including phase 3 studies in first-line lung cancer

    - PMLiVE

    Sanofi to expand immunology capabilities with $9.5bn Blueprint acquisition

    The deal will grant Sanofi access to a drug approved for the rare immunologic disorder systemic mastocytosis

    - PMLiVE

    Bristol Myers Squibb’s perioperative Opdivo regimen granted EC approval in NSCLC

    Up to 55% of patients with non-metastatic NSCLC develop recurrence despite curative resection

    - PMLiVE

    AbbVie and ADARx enter multi-billion dollar partnership to develop siRNA therapies

    The companies will focus on developing therapeutics across neuroscience, immunology and oncology

    - PMLiVE

    Bristol Myers Squibb’s injectable Opdivo formulation granted MHRA for solid tumours

    The new formulation reduces administration time from 30-to-60 minutes to three-to-five minutes

    - PMLiVE

    BMS receives NICE recommendation for immunotherapy combination in colorectal cancer

    Approximately 44,000 people are diagnosed with colorectal cancer in the UK every year

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links